Advertisement

Abciximab

  • Giuseppe Tridente
Chapter

Abstract

Abciximab (ReoPro®, Centocor, Eli Lilly) is an IgG1k Fab anti-GPIIb/IIIa chimeric monoclonal antibody (mAb) approved by FDA in 1993, by Health Canada in 1996, and by TGA (NZ) in 2005. In Europe the product was approved in some countries (UK, RoI), and under specific concertation procedures, but did not receive the final clearance from EMEA.

Keywords

Abciximab Bolus Acute Thrombocytopenia Final Clearance Heavy Chain Fragment Pulmonary Alveolar Hemorrhage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_5_MOESM1_ESM.xls (58 kb)
Supplementary material 1 (XLS 58 kb)

References

  1. 1.
    ReoPro® (Abciximab) BLA 97-0200/103575 medical review FDA Oct 1997Google Scholar
  2. 2.
    ReoPro® (Abciximab) Product Monograph. Eli Lilly Canada, Mar 2012Google Scholar
  3. 3.
    ReoPro® (Abciximab) Product Information Theory. Eur Heart J Eli Lilly/Janssen, Mar 2011Google Scholar
  4. 4.
    Califf RM (1997) The GUSTO trial and the open artery theory. Eur Heart J 18 (s):F2–F10Google Scholar
  5. 5.
    Askari AT, Lincoff AM (2002) GUSTO V: combination drug treatment of acute myocardial infarction. Clev Clin J Med 69:554–560CrossRefGoogle Scholar
  6. 6.
    Hook KM, Bennett JS (2004) Glycoprotein IIa/IIIa antagonists. In: Antiplatelet agents. P Gresele et al (eds) Springer, pp 200–218Google Scholar
  7. 7.
    Simon DI, Xu H, Ortlepp S, Rogers C et al (1997) 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17:528–535PubMedCrossRefGoogle Scholar
  8. 8.
    Mickelson JK, Ali MN, Kleiman NS et al (1999) Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 33:97–106PubMedCrossRefGoogle Scholar
  9. 9.
    Marciniak SJ, Mascelli MA, Furman MI et al (2002) An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 87:1020–1025PubMedGoogle Scholar
  10. 10.
    Kalra S, Bell MR, Rihal CS (2001) Alveolar hemorrhage as a complication of treatment with Abciximab. Chest 120:126–131PubMedCrossRefGoogle Scholar
  11. 11.
    Curtis BR, Swyers J, Divgi A et al (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99:2054–2059PubMedCrossRefGoogle Scholar
  12. 12.
    Tcheng JE, Kereiakes DJ, Lincoff AM et al (2001) Abciximab readministration. Results on the ReoPro readministration registry. Circulation 104:870–875PubMedCrossRefGoogle Scholar
  13. 13.
    Applegate RJ, Sacrinty MT, Kutcher MA et al (2008) Off-label stent therapy. 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 51:607–614PubMedCrossRefGoogle Scholar
  14. 14.
    Robinson M, Ginnelly L, Schulfer M et al (2002) A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIa antagonists. Health Technol Assessment 6: 1–171 (www.hta.ac.uk)Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations